Adaptive Clinical Trial

Studies,trials,treatments,type,adaptive designs,drugs,doses,clinical trials,clinical trial design,size,stage,phase,population,interim analyses,methods,outcome,rate,guidances,issue,design clinical,adaptive trial design,experimental treatment,advantage,benefit,adaptive trials,sample size,Food and Drug Administration,regulatory agencies,Guidance for Industry,activities.

Confirmatory trials,treatment arms,Adaptive design methods,adaptive methods,seamless phase,U.S. Food and Drug Administration,patient population,success rate,statistical inference,seamless design,sequential designs,ongoing trial,randomised trial,sample size re-estimation,effective treatments,statistical methods.

Clin Trials,Contemp Clin Trials,optimal dose,effective dose,control,agency,clinical benefit,lives,challenge,Gaydos B,practical guide,adaptive dose-finding designs,adaptive design trial,study sponsor,sample size calculation,maximum sample size,Continual reassessment method,confirmatory stage,planning stage,Clin Cancer Res,Berry DA,Berry SM,designs for phase,clinical outcomes,potential advantage,draft guidance,potential benefit,device,medical devices,Chow SC,Krams M,Exclusion Criteria,BMJ Open.

Chuang-Stein C,regulatory authorities,San Antonio,healthy volunteers,Inclusion Criteria,Clinical trial simulation,BATTLE trial,study objectives,observational studies,treatment under investigation,type of eligibility criteria,arm type,type of intervention model,Berry,primary outcome measure,target patient population,event rates,control arm,European Medicines Agency,biostatistician,Simon,Major issues,normal life functions,quality of life,major challenges,practical challenges,Gallo P,Pharm Stat,search feature,Ther Innov,Chang M,Stallard N,Bretz F,Dimairo M,8-digit number,Bayesian framework,identification code,North Carolina,Parmar MK,primary completion,responsible party,San Diego,San Francisco,birth defect,congenital anomaly,DeMets DL,Lewis RJ,Palo Alto,Hall/CRC Press,Trial examples,study day,learning stage,Clin Cancer,Berry D,infection control measures,ethical advantages,Academic biostatisticians,consultant biostatisticians,Simon R,Simon R.,ethical issues,limitation on activities,limitations on activities,flow oxygen devices.